Skip to content

ImmunoGen

Recent events

Recent events tied to this brand in public sources.

Back to profile2 entries

  1. 2024

    AbbVie completes acquisition of ImmunoGen

    AbbVie announced that it had completed its previously announced acquisition of ImmunoGen.

  2. 2022

    FDA grants accelerated approval for Elahere

    The US Food and Drug Administration granted accelerated approval for ImmunoGen’s Elahere to treat specified adult patients with FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer.